Answers are grounded in this paper and cite their sources.
Melanoma is a malignancy of melanocytes, most commonly arising in the skin. It is characterized by aggressive behavior and high metastatic potential [1]. Gastrointestinal metastasis is clinically diagnosed in only 2% of patients, contributing to frequent underdiagnosis [1]. Post-mortem prevalence was much higher, up to 60% [2]. The small bowel was the most common site, followed by the stomach [2], with fewer than 10% diagnosed during life [3]. Clinical manifestations are often vague and nonspecific—such as early satiety, nausea, weight loss, or anemia—contributing to delayed diagnosis [3]. Given its ability to mimic benign or primary gastric pathologies such as peptic ulcer disease, metastatic melanoma should remain in the differential diagnosis in patients with a remote history of cutaneous melanoma [4]. Here, we report a case of metastatic melanoma presenting with gastrointestinal bleeding, diagnosed endoscopically, to emphasize the need for a high index of suspicion in patients with a remote history of cutaneous melanoma. A 73-year-old man presented in 2024 with progressive fatigue, lightheadedness, and exertional dyspnea. His medical history was significant for a remote history of superficial spreading malignant melanoma of the left shoulder, diagnosed in 2007 (Breslow depth 0.49 mm, no nodal involvement). Being treated with wide local excision and no adjuvant therapy, he remained disease-free on surveillance until this presentation. Initial labs showed severe iron deficiency anemia (Hgb 5.5 g/dL) without overt gastrointestinal bleeding. After two units of packed red blood cells, esophagogastroduodenoscopy (EGD) revealed a large, friable polypoidal mass in the gastric body and prepyloric region with signs of recent bleeding (Figure 1). Histopathological analysis demonstrated sheets of atypical melanocytic cells with melanin pigment and prominent nucleoli. Immunohistochemistry was positive for S-100, HMB-45, Melan-A, and SOX-10, confirming the diagnosis of metastatic melanoma (Figure 1). Molecular profiling identified a non-V600E BRAF p. Ser467Leu (S467L) mutation. Staging with fluorine-18-labeled fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) revealed diffuse metastatic involvement, including multifocal gastric lesions and additional visceral and subcutaneous metastases. Magnetic resonance imaging of the brain showed no evidence of intracranial metastasis. The patient received four cycles of nivolumab and ipilimumab and discontinued this treatment after he developed Guillain–Barré syndrome, which has resolved with corticosteroids. Follow-up PET/CT showed resolution of metastatic lesions, and repeat EGD 6 months later demonstrated a decreased residual melanoma in the gastric body. He elected to hold off on further treatment. Gastric metastatic melanoma may closely mimic other gastric pathologies, including primary carcinoma, lymphoma, or peptic ulcer disease [4]. Endoscopy is essential for diagnosis, as it permits direct visualization and biopsy. Endoscopic appearances are variable, ranging from nodules to submucosal masses or ulcer-like lesions, most commonly involving the greater curvature and fundus [5]. In our case, it presented as a polypoidal mass, thereby underscoring the diagnostic challenges posed by its gross endoscopic appearance (Figure 1). Histologically, melanoma is characterized by pleomorphic epithelioid or spindle cells containing melanin pigment, although amelanotic variants may be more challenging to recognize. Immunohistochemical staining remains the cornerstone of diagnosis, with markers such as S-100, HMB-45, Melan-A/MART-1, and SOX10 demonstrating high sensitivity and specificity [1, 6]. Vimentin is also frequently expressed but lacks specificity due to its presence in a wide range of epithelial and mesenchymal tumors [6]. Imaging plays an important role in staging and surveillance. CT and PET/CT scans can identify mural masses or nodular lesions. Magnetic resonance imaging with diffusion-weighted imaging can aid in early detection due to melanoma’s high cellularity and melanin content, which produces hyperintense signals on T1-weighted sequences [5, 6]. At the molecular level, common oncogenic drivers in cutaneous melanoma include BRAF and NRAS mutations; KIT mutations are seen in mucosal and acral melanoma. BRAF mutations occur in approximately 50% of all cases, with the V600 variant accounting for nearly 90% of these cases [7]. In our case, the patient exhibited a BRAF mutation but no V600 variant, which is suspected in 5%–16% of melanomas [7]. Management of gastric metastatic melanoma depends on the extent of disease. In selected patients, surgical resection can provide symptom relief and may offer a survival advantage, with a reported median survival of 48.9 months vs less than 6 months for palliative therapy [2]. For disseminated disease, systemic therapy is the mainstay. Chemotherapy has limited efficacy, while immune checkpoint inhibitors—anti–PD-1 (nivolumab) and anti–CTLA-4 (ipilimumab)—have shown significant improvements in survival, especially in combination [8]. According to the 2023American Society of Clinical Oncology guidelines, patients with BRAF-mutant metastatic melanoma should receive immunotherapy (combined anti–PD-1/CTLA-4 followed by anti–PD-1 monotherapy), which yields higher response rates and longer progression-free survival [9]. In our case, immunotherapy was selected over resection due to diffuse metastases and over BRAF/MEK inhibitors, given limited evidence for non-V600 BRAF mutations. We suggest that post-treatment surveillance should primarily rely on clinical assessment and cross-sectional imaging, with endoscopy reserved for patients who develop new gastrointestinal symptoms or when there is clinical suspicion of recurrence, as no specific guidelines address routine repeat EGD following the initial diagnosis. PET/CT demonstrates higher sensitivity and specificity than CT for detecting gastrointestinal metastatic melanoma; however, the optimal imaging frequency remains undefined and should be individualized [2]. Fecal occult blood testing provides limited diagnostic value due to its low sensitivity for upper gastrointestinal bleeding and frequent false positives. Further studies are warranted to establish evidence-based surveillance algorithms for this population. Endoscopic and histopathologic confirmation of metastatic melanoma involving the stomach. (A) Wide-field endoscopic image showing a large, irregular, ulcerated, and friable gastric mass with erythematous surface and areas of spontaneous bleeding. (B) Hematoxylin and eosin (H&E) stain of gastric biopsy showing metastatic melanoma. The image demonstrates nests and sheets of atypical epithelioid cells with prominent nucleoli and occasional intracytoplasmic pigment, infiltrating the gastric mucosa and submucosa. (C) Immunohistochemical staining for SOX10. Nuclear staining is diffusely positive in tumor cells, further supporting the diagnosis of metastatic melanoma of gastric origin. Although gastric metastases from malignant melanoma are rare, early recognition is critical for effective management. Endoscopy with histopathologic confirmation remains the diagnostic gold standard. Surgical resection offers the best chance for prolonged survival in resectable disease, while immunotherapy has revolutionized treatment for advanced cases. This case underscores the need to consider metastatic melanoma in patients presenting with unexplained anemia, even years after presumed curative treatment. This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. M.M., Y.D., and M.G. conceived and designed the study. M.M. and M.G. collected the clinical data and prepared the figures. M.R. analyzed and interpreted the data and provided critical input from a gastroenterology perspective. M.M. drafted the initial manuscript, and Y.D. finalized the revisions. All authors read and approved the final manuscript. The authors declare that there is no conflict of interest in this study.
No takes yet. Share an insight, caveat, or question.
Martini et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: